Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 07, 2016 16:14 ET
|
Otonomy, Inc.
SAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
March 03, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Commercial Availability of OTIPRIO™
March 02, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at Cowen and Company Health Care Conference
February 29, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate Update
February 26, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
January 26, 2016 07:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy to Present at J.P. Morgan Healthcare Conference
January 08, 2016 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Added to NASDAQ Biotechnology Index
December 15, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces FDA Approval of OTIPRIO(TM) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
December 11, 2015 07:30 ET
|
Otonomy, Inc.
U.S. Commercial Launch Expected in the First Quarter of 2016
Webcast and Conference Call at 8:30 a.m. EST Today
SAN DIEGO, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a...
Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa
December 01, 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...